SUMMARY OF PRODUCT CHARACTERISTICS. Version: February (MRP variation number: NL/H/299/001/II/033 and NL/H/299/001/II/034)

Transcription

1 SUMMARY OF PRODUCT CHARACTERISTICS Version: February 2008 (MRP variation number: NL/H/299/001/II/033 and NL/H/299/001/II/034) 1

2 1. NAME OF THE MEDICINAL PRODUCT SPIRIVA 18 microgram, inhalation powder, hard capsule 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 22.5 microgram tiotropium bromide monohydrate equivalent to 18 microgram tiotropium. The delivered dose (the dose that leaves the mouthpiece of the HandiHaler device) is 10 microgram tiotropium. Excipient: Lactose monohydrate For a full list of excipients, see section PHARMACEUTICAL FORM Inhalation powder, hard capsule. Light green hard capsules with the product code TI 01 and company logo printed on the capsule. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Tiotropium is indicated as a maintenance bronchodilator treatment to relieve symptoms of patients with chronic obstructive pulmonary disease (COPD). 4.2 Posology and method of administration The recommended dosage of tiotropium bromide is inhalation of the contents of one capsule once daily with the HandiHaler device at the same time of day. The recommended dose should not be exceeded. Tiotropium bromide capsules must not be swallowed. Tiotropium bromide should only be inhaled with the HandiHaler device. Instructions for handling and use: Remember to carefully follow your doctor s instructions for using SPIRIVA. The HandiHaler is especially designed for SPIRIVA. You must not use it to take any other medication. You can use your HandiHaler for up to one year to take your medication. The HandiHaler 1 Dust cap 2 Mouthpiece 3 Base 4 Piercing button 5 Centre chamber 2

3 1. To release the dust cap press the piercing button completely in and let go. 2. Open the dust cap completely by pulling it upwards. Then open the mouthpiece by pulling it upwards. 3. Remove a SPIRIVA capsule from the blister (only immediately before use) and place it in the centre chamber (5), as illustrated. It does not matter which way the capsule is placed in the chamber. 4. Close the mouthpiece firmly until you hear a click, leaving the dust cap open. 5. Hold the HandiHaler device with the mouthpiece upwards and press the piercing button completely in only once, and release. This makes holes in the capsule and allows the medication to be released when you breathe in. 6. Breathe out completely. Important: Please avoid breathing into the mouthpiece at any time. 3

4 7. Raise the HandiHaler to your mouth and close your lips tightly around the mouthpiece. Keep your head in an upright position and breathe in slowly and deeply but at a rate sufficient to hear or feel the capsule vibrate. Breathe in until your lungs are full; then hold your breath as long as comfortable and at the same time take the HandiHaler out of your mouth. Resume normal breathing. Repeat steps 6 and 7 once, in order to empty the capsule completely. 8. Open the mouthpiece again. Tip out the used capsule and dispose. Close the mouthpiece and dust cap for storage of your HandiHaler device. Cleaning your HandiHaler Clean the HandiHaler once a month. Open the dust cap and mouthpiece. Then open the base by lifting the piercing button. Rinse the complete inhaler with warm water to remove any powder. Dry the HandiHaler thoroughly by tipping excess of water out on a paper towel and air-dry afterwards, leaving the dust cap, mouthpiece and base open. It takes 24 hours to air dry, so clean it right after you used it and it will be ready for your next dose. If needed, the outside of the mouthpiece may be cleaned with a moist but not wet tissue. Blister handling A. Separate the blister strips by tearing along the perforation. B. Peel back foil (only immediately before use) using the tab until one capsule is fully visible. In case a second capsule is exposed to air inadvertently this capsule has to be discarded. 4

5 C. Remove capsule. SPIRIVA capsules contain only a small amount of powder so that the capsule is only partially filled. Special Populations: Geriatric patients can use tiotropium bromide at the recommended dose. Renally impaired patients can use tiotropium bromide at the recommended dose. For patients with moderate to severe impairment (creatinine clearance 50 ml/min) see 4.4 Special warnings and special precautions for use and 5.2 Pharmacokinetic properties. Hepatically impaired patients can use tiotropium bromide at the recommended dose (see 5.2 Pharmacokinetic properties). Paediatric patients: Safety and effectiveness of tiotropium bromide inhalation powder in paediatric patients have not been established and therefore it should not be used in patients under 18 years of age. 4.3 Contraindications Tiotropium bromide inhalation powder is contraindicated in patients with a hypersensitivity to tiotropium bromide, atropine or its derivatives, e.g. ipratropium or oxitropium or to the excipient lactose monohydrate which contains milk protein. 4.4 Special warnings and precautions for use Tiotropium bromide, as a once daily maintenance bronchodilator, should not be used for the initial treatment of acute episodes of bronchospasm, i.e. rescue therapy. Immediate hypersensitivity reactions may occur after administration of tiotropium bromide inhalation powder. Consistent with its anticholinergic activity, tiotropium bromide should be used with caution in patients with narrow-angle glaucoma, prostatic hyperplasia or bladder-neck obstruction. (see 4.8 undesirable effects) Inhaled medicines may cause inhalation-induced bronchospasm. As plasma concentration increases with decreased renal function in patients with moderate to severe renal impairment (creatinine clearance 50 ml/min) tiotropium bromide should be used only if the expected benefit outweighs the potential risk. There is no long term experience in patients with severe renal impairment. (see 5.2 Pharmacokinetic properties). Patients should be cautioned to avoid getting the drug powder into their eyes. They should be advised that this may result in precipitation or worsening of narrow-angle glaucoma, eye pain or discomfort, temporary blurring of vision, visual halos or coloured images in association with red eyes from conjunctival congestion and corneal oedema. Should any combination of these eye symptoms develop, patients should stop using tiotropium bromide and consult a specialist immediately. 5

6 Dry mouth, which has been observed with anti-cholinergic treatment, may in the long term be associated with dental caries. Tiotropium bromide should not be used more frequently than once daily (see section 4.9 Overdose). SPIRIVA capsules contain 5.5 mg lactose monohydrate. 4.5 Interaction with other medicinal products and other forms of interaction Although no formal drug interaction studies have been performed, tiotropium bromide inhalation powder has been used concomitantly with other drugs without clinical evidence of drug interactions. These include sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids, commonly used in the treatment of COPD. The co-administration of tiotropium bromide with other anticholinergic-containing drugs has not been studied and is therefore not recommended. 4.6 Pregnancy and lactation For tiotropium bromide, no documented clinical data on exposed pregnancies are available. Studies in animals have shown reproductive toxicity associated with maternal toxicity (see section 5.3, Preclinical Safety Data). The potential risk for humans is unknown. Spiriva should therefore only be used during pregnancy when clearly indicated. It is unknown whether tiotropium bromide is excreted in human breast milk. Despite studies in rodents which have demonstrated that excretion of tiotropium bromide in breast milk occurs only in small amounts, use of Spiriva is not recommended during breast-feeding. Tiotropium bromide is a long-acting compound. A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with Spiriva should be made taking into account the benefit of breast-feeding to the child and the benefit of Spiriva therapy to the woman. 4.7 Effects on ability to drive and use machines No studies on the effects on the ability to drive and use machines have been performed. The occurrence of dizziness, blurred vision, or headache may influence the ability to drive and use machinery. 4.8 Undesirable effects a) General Description Many of the listed undesirable effects can be assigned to the anticholinergic properties of SPIRIVA. In controlled clinical studies, the most commonly observed undesirable effect was dry mouth which occurred in approximately 3% of patients. b) Table of Undesirable Effects The frequencies assigned to the undesirable effects listed below are based on crude incidence rates of adverse drug reactions (i.e. events attributed to tiotropium by study investigators) observed in the tiotropium group (5,437 patients) from 19 pooled placebo-controlled clinical trials with treatment periods ranging from four weeks to one year. MedDRA Preferred Term Frequency 1 Nervous system disorders Dizziness Headache Uncommon Uncommon 6

7 Taste disorders Eye disorders Vision blurred Intraocular pressure increased Glaucoma Cardiac disorders Tachycardia Palpitations Supraventricular tachycardia Atrial fibrillation Respiratory, thoracic and mediastinal disorders Bronchospasm Cough Pharyngitis and other application site irritation Dysphonia Epistaxis Sinusitis Uncommon Rare Rare Not known* Rare Rare Not known* Not known* Uncommon Uncommon Uncommon Uncommon Rare Not known* Gastrointestinal Disorders Dry Mouth Oral candidiasis Nausea Gastrooesophageal reflux disease Constipation Dental caries Dysphagia Intestinal obstruction, including ileus paralytic Skin and subcutaneous tissue disorders, Immune system disorders: Rash Urticaria Pruritus Other Hypersensitivity (including immediate reactions) Angioneurotic oedema Renal and Urinary Disorders Dysuria Urinary retention Urinary tract infection Common Uncommon Uncommon Rare Rare Not known* Not known* Not known* Rare Rare Rare Rare Not known* Rare Rare Rare 1 very common > 1/10; common > 1/100, < 1/10; uncommon > 1/1,000, < 1/100, rare >1/10,000, < 1/1,000 according to frequency convention *no events attributed to tiotropium by study investigators in 5,437 tiotropium treated patients; however, events are considered adverse drug reactions associated with tiotropium c) Information Characterising Individual Serious and/or Frequently Occurring Undesirable Effects 7

8 The most common anticholinergic undesirable effect reported by COPD patients was dry mouth. Dry mouth was mild in the majority of cases. In general, dry mouth had an onset between 3 and 5 weeks. Dry mouth commonly resolved while patients continued to receive tiotropium bromide. Dry mouth led to discontinuation from the one-year studies by 3 of 906 patients (0.3% of the treated patients). Serious undesirable effects consistent with anticholinergic effects include constipation and intestinal obstruction including ileus paralytic as well as urinary retention although none was attributed to tiotropium in the tiotropium group of 5,437 patients pooled from controlled clinical trials. d) Pharmacological Class - Undesirable effects Several organ systems and functions are under control of the parasympathetic nervous system and thus can be affected by anticholinergic agents. Possible adverse events attributable to systemic anticholinergic effects include dry mouth, dry throat, increased heart rate, blurred vision, increased intraocular pressure, glaucoma, urinary difficulty, urinary retention, and constipation. Urinary retention was usually observed in elderly men with predisposing factors, (e.g. prostatic hyperplasia). In common with all inhaled medications, tiotropium may cause inhalation-induced bronchospasm. Local upper airway irritant phenomena have also been observed in patients receiving tiotropium bromide. An increased incidence of dry mouth and constipation may occur with increasing age. 4.9 Overdose High doses of tiotropium bromide may lead to anticholinergic signs and symptoms. However, there were no systemic anticholinergic adverse effects following a single inhaled dose of up to 340 microgram tiotropium bromide in healthy volunteers. Additionally, no relevant adverse effects, beyond dry mouth, were observed following 7 day dosing of up to 170 microgram tiotropium bromide in healthy volunteers. In a multiple dose study in COPD patients with a maximum daily dose of 43 microgram tiotropium bromide over four weeks no significant undesirable effects have been observed. Acute intoxication by inadvertent oral ingestion of tiotropium bromide capsules is unlikely due to low oral bioavailability 5. PHARMACOLOGICAL PROPERTIES 5.1 Pharmacodynamic properties Pharmacotherapeutic group: Anticholinergics, ATC code: R03B B04 Tiotropium bromide is a long-acting, specific, muscarinic receptor antagonist, in clinical medicine often called an anticholinergic. By binding to the muscarinic receptors in the bronchial smooth musculature, tiotropium bromide inhibits the cholinergic (bronchoconstrictive) effects of acetylcholine, released from parasympathetic nerve endings. It has similar affinity to the subtypes of muscarinic receptors, M 1 to M 5 In the airways, tiotropium bromide competitively and reversibly antagonises the M 3 receptors, resulting in relaxation. The effect was dose dependent and lasted longer than 24h. The long duration is probably due to the very slow dissociation from the M 3 receptor, exhibiting a significantly longer dissociation half-life than ipratropium. As an N-quaternary anticholinergic, tiotropium bromide is topically (broncho-) selective when administered by inhalation, demonstrating an acceptable therapeutic range before systemic anticholinergic effects may occur. The bronchodilation is primarily a local effect (on the airways), not a systemic one. Dissociation from M 2 -receptors is faster than from M 3, which in functional in vitro studies, elicited (kinetically controlled) receptor subtype selectivity of M 3 over M 2. The high potency and slow receptor dissociation found its clinical correlate in significant and long-acting bronchodilation in patients with COPD. 8

9 Electrophysiology: In a dedicated QT study involving 53 healthy volunteers, SPIRIVA 18 mcg and 54 mcg (i.e. three times the therapeutic dose) over 12 days did not significantly prolong QT intervals of the ECG. The clinical development programme included four one-year and two six-month randomised, double-blind studies in 2663 patients (1308 receiving tiotropium bromide). The one-year programme consisted of two placebo-controlled trials and two trials with an active control (ipratropium). The two six-month trials were both, salmeterol and placebo controlled. These studies included lung function and health outcome measures of dyspnea, exacerbations and health-related quality of life. In the aforementioned studies, tiotropium bromide, administered once daily, provided significant improvement in lung function (forced expiratory volume in one second, FEV 1 and forced vital capacity, FVC) within 30 minutes following the first dose which was maintained for 24 hours. Pharmacodynamic steady state was reached within one week with the majority of bronchodilation observed by the third day. Tiotropium bromide significantly improved morning and evening PEFR (peak expiratory flow rate) as measured by patient s daily recordings. The bronchodilator effects of tiotropium bromide were maintained throughout the one-year period of administration with no evidence of tolerance. A randomised, placebo-controlled clinical study in 105 COPD patients demonstrated that bronchodilation was maintained throughout the 24 hour dosing interval in comparison to placebo regardless of whether the drug was administered in the morning or in the evening. The following health outcome effect was demonstrated in the long term (6-month and to one-year) trials: Tiotropium bromide significantly improved dyspnea (as evaluated using the Transition Dyspnea Index.). This improvement was maintained throughout the treatment period. The impact of improvements in dyspnea on exercise tolerance was investigated in two randomised, doubleblind, placebo-controlled trials in 433 patients with moderate to severe COPD. In these trials, six weeks of treatment with SPIRIVA significantly improved symptom-limited exercise endurance time during cycle ergometry at 75% of maximal work capacity by 19.7% (Trial A: 640 seconds with SPIRIVA vs. 535 seconds with placebo, compared with a pre-treatment baseline of 492 seconds) and 28.3% (Trial B: 741 seconds with SPIRIVA vs. 577 seconds with placebo, compared with a pre-treatment baseline of 537 seconds). In a randomized, double-blind, placebo controlled trial of 1,829 patients with moderate to very severe COPD, tiotropium bromide statistically significantly reduced the proportion of patients who experienced exacerbations of COPD (32.2% to 27.8%) and statistically significantly reduced the number of exacerbations by 19% (1.05 to 0.85 events per patient year of exposure). In addition, 7.0% of patients in the tiotropium bromide group and 9.5% of patients in the placebo group were hospitalized due to a COPD exacerbation (p=0.056). The number of hospitalizations due to COPD was reduced by 30% (0.25 to 0.18 events per patient year of exposure). In a 9-month, randomized, double-blind, placebo-controlled clinical trial of 492 patients, SPIRIVA improved health-related quality of life as determined by the St. George s Respiratory Questionnaire (SGRQ) total score. The proportion of patients treated with SPIRIVA which achieved a meaningful improvement in the SGRQ total score (i.e. > 4 units) was 10.9% higher compared with placebo (59,1% in the SPIRIVA groups vs. 48.2% in the placebo group (p=0.029). The mean difference between the groups was 4.19 units (p=0.001; confidence interval: ). While the SGRQ subdomains "activity" and "impact on daily life" were not improved significantly, the improvement on total score resulted from a marked improvement in the SGRQ subdomain disease related "symptoms". 5.2 Pharmacokinetic properties a) General Introduction 9

10 Tiotropium bromide is a non-chiral quaternary ammonium compound and is sparingly soluble in water. Tiotropium bromide is administered by dry powder inhalation. Generally with the inhaled route of administration, the majority of the delivered dose is deposited in the gastro-intestinal tract, and to a lesser extent in the intended organ of the lung. Many of the pharmacokinetic data described below were obtained with higher doses than recommended for therapy. b) General Characteristics of the Active Substance after Administration of the Medicinal Product Absorption: Following dry powder inhalation by young healthy volunteers, the absolute bioavailability of 19.5% suggests that the fraction reaching the lung is highly bioavailable. It is expected from the chemical structure of the compound (quaternary ammonium compound) and from in-vitro experiments that tiotropium bromide is poorly absorbed from the gastrointestinal tract (10-15%). Oral solutions of tiotropium bromide have an absolute bioavailability of 2-3%. Maximum tiotropium bromide plasma concentrations were observed five minutes after inhalation. Food is not expected to influence the absorption of this quaternary ammonium compound. Distribution: The drug is bound by 72% to plasma proteins and shows a volume of distribution of 32 L/kg. At steady state, tiotropium bromide plasma levels in COPD patients at peak were pg/ml when measured 5 minutes after dry powder inhalation of a 18 microgram dose and decreased rapidly in a multicompartmental manner. Steady state trough plasma concentrations were 3-4 pg/ml. Local concentrations in the lung are not known, but the mode of administration suggests substantially higher concentrations in the lung. Studies in rats have shown that tiotropium bromide does not penetrate the blood-brain barrier to any relevant extent. Biotransformation: The extent of biotransformation is small. This is evident from a urinary excretion of 74% of unchanged substance after an intravenous dose to young healthy volunteers. The ester tiotropium bromide is nonenzymatically cleaved to the alcohol (N-methylscopine) and acid compound (dithienylglycolic acid) that are inactive on muscarinic receptors. In-vitro experiments with human liver microsomes and human hepatocytes suggest that some further drug (< 20% of dose after intravenous administration) is metabolised by cytochrome P450 (CYP) dependent oxidation and subsequent glutathion conjugation to a variety of Phase II-metabolites. In vitro studies in liver microsomes reveal that the enzymatic pathway can be inhibited by the CYP 2D6 (and 3A4) inhibitors, quinidine, ketoconazole and gestodene. Thus CYP 2D6 and 3A4 are involved in metabolic pathway that is responsible for the elimination of a smaller part of the dose. Tiotropium bromide even in supra-therapeutic concentrations does not inhibit CYP 1A1, 1A2, 2B6, 2C9, 2C19, 2D6, 2E1 or 3A in human liver microsomes. Elimination: The terminal elimination half-life of tiotropium bromide is between 5 and 6 days following inhalation. Total clearance was 880 ml/min after an intravenous dose in young healthy volunteers with an interindividual variability of 22%. Intravenously administered tiotropium bromide is mainly excreted unchanged in urine (74%). After dry powder inhalation urinary excretion is 14% of the dose, the remainder being mainly non-absorbed drug in gut that is eliminated via the faeces. The renal clearance of tiotropium bromide exceeds the creatinine clearance, indicating secretion into the urine. After chronic once daily inhalation by COPD patients, pharmacokinetic steady state was reached after 2-3 weeks with no accumulation thereafter. Linearity / Nonlinearity: Tiotropium bromide demonstrates linear pharmacokinetics in the therapeutic range after both intravenous administration and dry powder inhalation. c) Characteristics in Patients Geriatric Patients: As expected for all predominantly renally excreted drugs, advanced age was associated with a decrease of tiotropium bromide renal clearance (326 ml/min in COPD patients < 58 years to 163 ml/min in COPD patients > 70 years) which may be explained by decreased renal function. Tiotropium bromide excretion in urine after inhalation decreased from 14% (young healthy volunteers) to about 7% (COPD patients), however plasma concentrations did not change significantly with advancing age within 10

11 COPD patients if compared to inter- and intraindividual variability (43% increase in AUC 0-4h after dry powder inhalation. Renally Impaired Patients: In common with all other drugs that undergo predominantly renal excretion, renal impairment was associated with increased plasma drug concentrations and reduced renal drug clearance after both intravenous infusion and dry powder inhalations. Mild renal impairment (CL CR ml/min) which is often seen in elderly patients increased tiotropium bromide plasma concentrations slightly (39% increase in AUC 0-4h after intravenous infusion). In COPD patients with moderate to severe renal impairment (CL CR < 50 ml/min) the intravenous administration of tiotropium bromide resulted in doubling of the plasma concentrations (82% increase in AUC 0-4h ), which was confirmed by plasma concentrations after dry powder inhalation. Hepatically Impaired Patients: Liver insufficiency is not expected to have any relevant influence on tiotropium bromide pharmacokinetics. Tiotropium bromide is predominantly cleared by renal elimination (74% in young healthy volunteers) and simple non-enzymatic ester cleavage to pharmacologically inactive products. Paediatric Patients: See 4.2 Posology and Method of Administration d) Pharmacokinetic / Pharmacodynamic Relationship(s) There is no direct relationship between pharmacokinetics and pharmacodynamics. 5.3 Preclinical safety data Many effects observed in conventional studies of safety pharmacology, repeated dose toxicity, and reproductive toxicity could be explained by the anticholinergic properties of tiotropium bromide. Typically in animals reduced food consumption, inhibited body weight gain, dry mouth and nose, reduced lacrimation and salivation, mydriasis and increased heart rate were observed. Other relevant effects noted in repeated dose toxicity studies were: mild irritancy of the respiratory tract in rats and mice evinced by rhinitis and epithelial changes of the nasal cavity and larynx, and prostatitis along with proteinaceous deposits and lithiasis in the bladder in rats. Harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development could only be demonstrated at maternally toxic dose levels. Tiotropium bromide was not teratogenic in rats or rabbits. The respiratory (irritation) and urogenital (prostatitis) changes and reproductive toxicity were observed at local or systemic exposures more than five-fold the therapeutic exposure. Studies on genotoxicity and carcinogenic potential revealed no special hazard for humans. 6. PHARMACEUTICAL PARTICULARS 6.1 List of excipients Lactose monohydrate (which contains milk protein) 6.2 Incompatibilities Not applicable. 6.3 Shelf life 2 years After first opening of the blister: 9 days Discard the HandiHaler device 12 months after first use. 11

12 6.4 Special precautions for storage Do not store above 25 C Do not freeze. 6.5 Nature and contents of container Aluminium / PVC / Aluminium blister strips containing 10 capsules. The HandiHaler is a single dose inhalation device made from plastic materials (ABS) and stainless steel. Package sizes and devices supplied: Cardboard box containing 30 capsules (3 blister strips) Cardboard box containing 60 capsules (6 blister strips) Cardboard box containing 90 capsules (9 blister strips) Cardboard box containing HandiHaler device Cardboard box containing HandiHaler device and 10 capsules (1 blister strip) Cardboard box containing HandiHaler device and 30 capsules (3 blister strips) Hospital pack: Bundle pack containing 5 cardboard boxes of 30 capsules plus HandiHaler device Hospital pack: Bundle pack containing 5 cardboard boxes of 60 capsules Not all pack sizes may be marketed 6.6 Special precautions for disposal No special requirements. 7. MARKETING AUTHORISATION HOLDER Boehringer Ingelheim International GmbH Binger Straße 173 D Ingelheim am Rhein Germany 8. MARKETING AUTHORISATION NUMBER(S) <[To be completed nationally]> 9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION <{DD/MM/YYYY}> <{DD month YYYY}> 10. DATE OF REVISION OF THE TEXT {MM/YYYY} 12

13 LABELLING AND PACKAGE LEAFLET Depending on local legislation, package material prints may contain the company logo of the co-promotion partner Pfizer 13

14 A. LABELLING 14

15 PARTICULARS TO APPEAR ON THE OUTER PACKAGING Folding Box 1 HandiHaler device plus XX capsules in blisters (Combo Pack) HandiHaler 1. NAME OF THE MEDICINAL PRODUCT SPIRIVA 18 microgram, inhalation powder, hard capsule Tiotropium 2. STATEMENT OF ACTIVE SUBSTANCE(S) Each capsule contains 18 microgram tiotropium (as bromide monohydrate) 3. LIST OF EXCIPIENTS Lactose monohydrate For further information, please refer to the Package Leaflet. 4. PHARMACEUTICAL FORM AND CONTENTS Inhalation powder, hard capsule HandiHaler device and 10 capsules (1 blister strip) HandiHaler device and 30 capsules (3 blister strips) Hospital pack: Bundle pack containing 5 cardboard boxes of 30 capsules plus HandiHaler device 5. METHOD AND ROUTE(S) OF ADMINISTRATION Inhale the contents of a capsule using the HandiHaler device. Read the package leaflet and the separate instructions for use of the HandiHaler device before use. Do not swallow the capsules 6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN Keep out of the reach and sight of children. 7. OTHER SPECIAL WARNING(S), IF NECESSARY Not applicable 8. EXPIRY DATE EXP MM-YYYY After first opening of the blister strip, use within 9 days. After starting to use, discard the HandiHaler device after 12 months. 9. SPECIAL STORAGE CONDITIONS 15

16 Do not store above 25 C Do not freeze 10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE Not applicable 11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER Boehringer Ingelheim International GmbH D Ingelheim am Rhein Germany 12. MARKETING AUTHORISATION NUMBER(S) Country specific 13. BATCH NUMBER BN 14. GENERAL CLASSIFICATION FOR SUPPLY Medicinal product subject to medical prescription. 15. INSTRUCTIONS ON USE Not applicable 16. INFORMATION IN BRAILLE SPIRIVA 18 + HandiHaler Additionally: Manufacturer of the HandiHaler device: Boehringer Ingelheim Pharma GmbH & Co. KG D Ingelheim am Rhein Germany CE mark (Sample packs only: Sample pack. Free medical sample not for resale) 16

17 17

18 PARTICULARS TO APPEAR ON THE OUTER PACKAGING Folding Box XX capsules in blisters (Refill) 1. NAME OF THE MEDICINAL PRODUCT SPIRIVA 18 microgram Inhalation powder, hard capsule Tiotropium 2. STATEMENT OF ACTIVE SUBSTANCE(S) Each capsule contains 18 microgram tiotropium (as bromide monohydrate) 3. LIST OF EXCIPIENTS Lactose monohydrate For further information, please refer to the Package Leaflet. 4. PHARMACEUTICAL FORM AND CONTENTS Inhalation powder, hard capsule 30 capsules (3 blister strips) 60 capsules (6 blister strips) 90 capsules (9 blister strips) Hospital pack: Bundle pack containing 5 cardboard boxes of 60 capsules 5. METHOD AND ROUTE(S) OF ADMINISTRATION Inhale the contents of a capsule using the HandiHaler device. Read the package leaflet and the separate instructions for use of the HandiHaler device before use. Do not swallow the capsules 6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN Keep out of the reach and sight of children. 7. OTHER SPECIAL WARNING(S), IF NECESSARY Not applicable 8. EXPIRY DATE EXP MM YYYY After first opening of the blister strip, use within 9 days. 9. SPECIAL STORAGE CONDITIONS 18

19 Do not store above 25 C Do not freeze 10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE Nota applicable 11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER Boehringer Ingelheim International GmbH D Ingelheim am Rhein Germany 12. MARKETING AUTHORISATION NUMBER(S) Country specific 13. BATCH NUMBER BN 14. GENERAL CLASSIFICATION FOR SUPPLY Medicinal product subject to medical prescription. 15. INSTRUCTIONS ON USE Not applicable 16. INFORMATION IN BRAILLE SPIRIVA 18 In addition: 19

20 (Sample packs only: Sample pack. Free medical sample not for resale) 20

21 PARTICULARS TO APPEAR ON THE OUTER PACKAGING HandiHaler 1. NAME OF THE MEDICAL DEVICE HandiHaler 2. STATEMENT OF ACTIVE SUBSTANCE(S) Not applicable 3. LIST OF EXCIPIENTS Not applicable 4. PHARMACEUTICAL FORM AND CONTENTS Not applicable Cardboard box containing HandiHaler device 5. METHOD AND ROUTE(S) OF ADMINISTRATION Before use carefully read the enclosed instructions for use. For use with SPIRIVA 18 microgram Inhalation Powder, Hard Capsule 6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN Keep out of the reach and sight of children. 7. OTHER SPECIAL WARNING(S), IF NECESSARY Not applicable 8. EXPIRY DATE After starting to use, discard after 12 months. 9. SPECIAL STORAGE CONDITIONS Do not store above 25 C Do not freeze 10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE 21

22 Not applicable 11. NAME AND ADDRESS OF THE MANUFACTURER Boehringer Ingelheim Pharma GmbH & Co. KG D Ingelheim am Rhein Germany 12. MARKETING AUTHORISATION NUMBER(S) Not applicable 13. BATCH NUMBER 14. GENERAL CLASSIFICATION FOR SUPPLY Not applicable 15. INSTRUCTIONS ON USE Not applicable 16. INFORMATION IN BRAILLE HandiHaler Additionally: CE mark (Sample packs only: Sample pack. Free medical sample not for resale) 22

23 MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS Blister: Alu/PVC/Alu 1. NAME OF THE MEDICINAL PRODUCT SPIRIVA 18 microgram, inhalation powder hard capsule Tiotropium 2. NAME OF THE MARKETING AUTHORISATION HOLDER Boehringer Ingelheim, BI Logo 3. EXPIRY DATE EXP 4. BATCH NUMBER BN 5. OTHER Open on other side only Inhalation use Separate here Peel back up to line Push capsule out ----Stop--- 23

24 B. PACKAGE LEAFLET 24

25 PACKAGE LEAFLET: INFORMATION FOR THE USER SPIRIVA 18 microgram, inhalation powder, hard capsule tiotropium Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. - If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. In this leaflet: 1. What SPIRIVA 18 microgram is and what it is used for 2. Before you take SPIRIVA 18 microgram 3. How to take SPIRIVA 18 microgram 4. Possible side effects 5. How to store SPIRIVA 18 microgram 6. Further information 1. WHAT SPIRIVA 18 MICROGRAM IS AND WHAT IT IS USED FOR SPIRIVA 18 microgram helps people who have chronic obstructive pulmonary disease (COPD) to breathe more easily. COPD is a chronic lung disease that causes shortness of breath and coughing. The term COPD is associated with the conditions chronic bronchitis and emphysema. As COPD is a chronic disease you should take SPIRIVA 18 microgram every day and not only when you have breathing problems or other symptoms of COPD. SPIRIVA 18 micorgram is a long-acting bronchodilator that helps to open your airways and makes it easier to get air in and out of the lungs. Regular use of SPIRIVA 18 microgram can also help you when you have on-going shortness of breath related to your disease and will help you to minimise the effects of the disease on your everyday life. It also helps you to be active longer. Daily use of SPIRIVA 18 microgram will also help to prevent sudden, short-term worsening of your COPD symptoms which may last for several days. The effect of this medicine lasts for 24 hours, so you only need to take it once a day. For correct dosing of SPIRIVA 18 microgram please see section 3. How to take SPIRIVA 18 microgram and the instructions for use provided on the other side of the leaflet. 2. BEFORE YOU TAKE SPIRIVA 18 MICROGRAM Please read the following questions carefully. If you can answer any of these questions with `Yes` please discuss this with your doctor before taking SPIRIVA 18 microgram - are you allergic to tiotropium, atropine or similar drugs such as ipratropium or oxitropium or to lactose or milk protein - are you taking any other medicinal products containing ipratropium or oxitropium? - are you pregnant, do you think you are pregnant, or are you breast-feeding? - are you suffering from narrow angle glaucoma, prostate problems or have difficulty passing urine? - do you have any kidney problems? Do not take SPIRIVA 18 microgram You should not use SPIRIVA 18 microgram if you are allergic (hypersensitive) to tiotropium or to lactose monohydrate which contains milk protein. 25

26 You should also not use SPIRIVA 18 microgram if you are allergic (hypersensitive) to atropine or substances related to it, e.g. ipratropium or oxitropium You should not use SPIRIVA 18 microgram if you are under 18 years of age. Take special care with SPIRIVA 18 microgram - if you suffer from narrow angle glaucoma, prostate problems or have difficulty passing urine - if you have problems with your kidneys - SPIRIVA 18 microgram is indicated for maintenance treatment of your chronic obstructive pulmonary disease, it should not be used to treat a sudden attack of breathlessness or wheezing. - Immediate allergic reactions such as rash, swelling, itching, wheezing or breathlessness may occur after administration of SPIRIVA 18 microgram. If this occurs, please consult your doctor immediately. - Inhaled medicines such as SPIRIVA 18 microgram may cause tightness of the chest, coughing, wheezing or breathlesness immediately after inhalation. If this occurs, please consult your doctor immediately. - Take care not to let the inhalation powder enter your eye as this may result in precipitation or worsening of narrow-angle glaucoma, which is a disease of the eyes. Eye pain or discomfort, blurred vision, seeing halos around lights or coloured images in association with red eyes may be signs of narrow-angle glaucoma. Eye symptoms may be accompanied by headache, nausea or vomiting. You should stop using tiotropium bromide and immediately consult your doctor, preferably an eye specialist, when signs and symptoms of narrow-angle glaucoma appear. - Dry mouth, which has been observed with anti-cholinergic treatment, may in the long term be associated with dental caries. Therefore, please remember to pay attention to oral hygiene. - Do not take SPIRIVA 18 microgram more frequently than once daily. Taking other medicines Please inform your doctor or pharmacist if you are taking, or have recently taken, any other medicines, even those not prescribed. Please tell your doctor or pharmacist if you are taking/have taken similar medicines for your lung disease, such as ipratropium or oxitropium. No specific side effects have been reported when SPIRIVA 18 microgram has been taken together with other products used to treat COPD such as reliever inhalers e.g. salbutamol, methylxanthines e.g. theophylline and/or oral and inhaled steroids e.g. prednisolone. Pregnancy and breast-feeding If you are pregnant or believe you are pregnant, or if you are breast-feeding, consult with your doctor. You should not use this medicine unless specifically recommended by your doctor. Driving and using machines The occurrence of dizziness, blurred vision, or headache may influence the ability to drive and use machinery. Important information about some of the ingredients of SPIRIVA 18 microgram When taken according to dosage recommendations, one capsule once a day, each dose supplies up to 5.5 mg lactose monohydrate. 3. HOW TO TAKE SPIRIVA 18 MICROGRAM Follow your doctor s instructions about when and how to take your medicine. If you are unsure ask your doctor or pharmacist. 26

27 The recommended dose is to inhale the contents of 1 capsule (18 micrograms of tiotropium) once a day. Do not take more than the recommended dose. You should try to take the capsule at the same time every day. This is important because SPIRIVA 18 mcirogram is effective over 24 hours. Do not swallow the capsules. The HandiHaler device, which you should put the SPIRIVA capsule into, makes holes in the capsule and allows you to breathe in the powder. Make sure that you have a HandiHaler and that you can use it properly. The instructions for use of the HandiHaler are provided on the other side of this leaflet. Make sure that you do not blow into the HandiHaler. If you have any problems using the HandiHaler, ask your doctor, nurse or pharmacist to show you how it works. You should clean your HandiHaler once a month. Cleaning instructions for the HandiHaler are provided on the other side of this leaflet. When taking SPIRIVA 18 microgram, take care not to let any of the powder enter your eyes. If any powder does get into your eyes you may get blurred vision, eye pain and/or red eyes, you should wash your eyes in warm water immediately. Then talk to your doctor immediately for further advice. If you feel that your breathing is worsening, you should tell your doctor as soon as possible If you take more SPIRIVA 18 microgram than you should If you inhale from more than 1 capsule of SPIRIVA 18 microgram in a day, you should talk to your doctor immediately. You may be at a higher risk of experiencing a side effect such as dry mouth, constipation, difficulties passing urine, increased heart beat, or blurred vision. If you forget to take SPIRIVA 18 microgram If you forget to take a dose, take one as soon as you remember but do not take two doses at the same time or on the same day. Then take your next dose as usual. If you stop taking SPIRIVA 18 microgram Before you stop taking Spiriva 18 microgram, you should talk to your doctor or your pharmacist. If you stop taking SPIRIVA 18 microgram the signs and symptoms of COPD may worsen. If you have any further questions on the use of this product, ask your doctor. 4. POSSIBLE SIDE EFFECTS Like all medicines, SPIRIVA 18 microgram can cause side effects, although not everybody gets them. The most common side effect with SPIRIVA 18 microgram is dry mouth (experienced in approximately 3%of patients). This is usually mild and often stops on continuing treatment. There are some side effects that are uncommon (in 0.1-1% of patients). These are: dizziness, headache, nausea, tightness of the chest, coughing, wheezing or breathlesness, cough, sore throat, hoarseness, fungal infection in the mouth, taste disorders. 27

28 Other side effects occur rarely ( % of patients) Those are: blurred vision, increased measured eye pressure, increased heart beat, nose bleed, heart burn, constipation, rash, nettle rash, itching, difficulty passing urine (especially if you already have problems passing urine) and urinary infection. Immediate allergic reactions such as rash, swelling, itching, wheezing or breathlessness may occur after administration of SPIRIVA 18 microgram. If this occurs, please consult your doctor immediately. Additionally, you may experience irregular heart beat, eye pain or discomfort, blurred vision, seeing halos around lights or coloured images in association with red eyes, inflammation of the sinuses, blockage in the intestines including paralysis of the bowel which may present as severe constipation or absence of movement in the bowel and may lead to blockage in the stomach, difficulties swallowing and dental caries. You may also experience swelling of mouth and face which may be accompanied by trouble breathing. If this occurs, please consult your doctor immediately. In addition, in common with all inhaled medicines, some patients may experience a tightness of the chest, coughing, wheezing or breathlessness immediately after inhalation. If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. 5. HOW TO STORE SPIRIVA 18 microgram Keep out of the reach and sight of children. Do not use SPIRIVA 18 microgram after the expiry date which is stated on the carton and the blister foil. The expiry date refers to the last day of that month. Once you have taken your first capsule from the blister strip you must continue to take the capsules for the next 9 days, one capsule a day, from the same strip. Do not store above 25 C. Do not freeze. Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment. 6. FURTHER INFORMATION What SPIRIVA 18 microgram contains Each capsule contains 18 micrograms of the active ingredient tiotropium (as bromide monohydrate). During inhalation, 10 micrograms tiotropium are delivered from the mouthpiece of the HandiHaler. The other ingredient is lactose monohydrate What SPIRIVA 18 microgram looks like and contents of the pack SPIRIVA 18 microgram, inhalation powder, hard capsule is a light green hard capsules with the product code TI 01 and company logo printed on the capsule. The product is available in the following packs: A pack containing 30 capsules A pack containing 60 capsules A pack containing 90 capsules A pack containing 1 HandiHaler A pack containing 10 capsules and 1 HandiHaler A pack containing 30 capsules and 1 HandiHaler Hospital pack: Bundle pack containing 5 cardboard boxes of 30 capsules plus HandiHaler device 28

29 Hospital pack: Bundle pack containing 5 cardboard boxes of 60 capsules Not all pack sizes may be marketed Marketing Authorisation Holder and Manufacturer The marketing authorisationholder for SPIRIVA 18 microgram is: Boehringer Ingelheim International GmbH Binger Straße 173 D Ingelheim am Rhein Germany The manufacturer for SPIRIVA 18 microgram and the HandiHaler device is: Boehringer Ingelheim Pharma GmbH & Co. KG Binger Straße 173 D Ingelheim am Rhein Germany This medicinal product is authorised in the member States of the EEA under the tradename SPIRIVA 18 microgram. This leaflet was last approved in {MM/YYYY}. 29

30 HandiHaler instructions for use: Dear Patient, The HandiHaler enables you to inhale the medicine contained in the Spiriva capsule that your physician has prescribed for your breathing problems. Remember to carefully follow your doctor s instructions for using SPIRIVA. The HandiHaler is especially designed for SPIRIVA. You must not use it to take any other medication. You can use your HandiHaler for up to one year to take your medication. The HandiHaler 1 Dust cap 2 Mouthpiece 3 Base 4 Piercing button 5 Centre chamber 1. To release the dust cap press the piercing button completely in and let go. 2. Open the dust cap completely by pulling it upwards. Then open the mouthpiece by pulling it upwards. 3. Remove a SPIRIVA capsule from the blister (only immediately before use, see blister handling) and place it in the centre chamber. Put the SPIRIVA capsule in the centre chamber (5), as illustrated. It does not matter which way the capsule is placed in the chamber. 30

31 4. Close the mouthpiece firmly until you hear a click, leaving the dust cap open. 5. Hold the HandiHaler device with the mouthpiece upwards and press the piercing button completely in only once, and release. This makes holes in the capsule and allows the medication to be released when you breathe in. 6. Breathe out completely. Important: Please avoid breathing into the mouthpiece at any time. 7. Raise the HandiHaler to your mouth and close your lips tightly around the mouthpiece. Keep your head in an upright position and breathe in slowly and deeply but at a rate sufficient to hear or feel the capsule vibrate. Breathe in until your lungs are full; then hold your breath as long as comfortable and at the same time take the HandiHaler out of your mouth. Resume normal breathing. Repeat steps 6 and 7 once, in order to empty the capsule completely. 8. Open the mouthpiece again. Tip out the used capsule and dispose. Close the mouthpiece and dust cap for storage of your HandiHaler device. Cleaning your HandiHaler Clean the HandiHaler once a month. Open the dust cap and mouthpiece. Then open the base by lifting the piercing button. Rinse the complete inhaler with warm water to remove any powder. Dry the HandiHaler thoroughly by tipping excess of water out on a paper towel and air-dry afterwards, leaving the dust cap, mouthpiece and base open. It takes 24 hours to air dry, so clean it right after you used it and it will be ready for your next dose. If needed, the outside of the mouthpiece may be cleaned with a moist but not wet tissue. Blister handling 31

32 A Separate the blister strips by tearing along the perforation. B. Peel back foil (only immediately before use) using the tab until one capsule is fully visible. In case a second capsule is exposed to air inadvertently this capsule has to be discarded. C. Remove capsule. SPIRIVA capsules contain only a small amount of powder so that the capsule is only partially filled. CE mark Manufacturer of the HandiHaler device: Boehringer Ingelheim Pharma GmbH & Co. KG D Ingelheim am Rhein Germany 32